Supply Costs Sample Clauses

Supply Costs. [***] As further described below in Section 6.2 and 6.3, the Clinical Supply Costs incurred in accordance with the GDP for clinical supplies of Product used in activities under the GDP shall be included in Development Costs, and the Commercial Supply Costs (as defined below) incurred in accordance with the applicable Commercialization Plan (and the applicable Supply Agreement) for commercial supplies of Product for distribution in the U.S., Xxxxxxx Territory and Greater China shall be included in Allowable Expenses.
Sample 1Sample 2
AutoNDA by SimpleDocs
Supply Costs. Catalyst shall pay BioMarin for Manufacturing and supply of Firdapse in accordance with the terms set forth in Article 5. EXECUTION VERSION
Sample 1Sample 2
Supply Costs. The Fully Burdened Manufacturing Costs of Clinical Supplies and Commercial Supplies (other the costs of Clinical Supplies included within Initial Indication Development Costs) shall be Shared Expenses and shall be subject to offset or credit against amounts due pursuant to Section 9.5 below.
Sample 1Sample 2
Supply Costs. Regarding the supply costs, the Individual Contracts shall be based on a “cost plus principle” ***. The cost base for the calculation of the supply costs shall be *** as reasonably calculated by VW T&B. ***. The estimated warranty costs as mutually agreed will be part of the cost base and not part of the xxxx-up. The xxxx-up level will in general be ***. In general, ***. The above xxxx-up range of *** shall apply to the products described in Section 4.1 above. The supply costs for other products referred to in Section 4.2 and Section 4.3 above shall be discussed by the Parties in due course.
Sample 1
Supply Costs. Subject to Section 6.3, all costs incurred after October 1, 2005 related to manufacture, packaging and distribution of Drug Substance and Product will be borne by Forest; provided, however, that, with regard to validation batches of Drug Substance for which the parties may agree to pay NISSO and DAP in advance, subject to refund if such validation batches do not meet the specified requirements, [ *** ], Replidyne shall promptly [ *** ]. Replidyne shall have the right, in its sole discretion, to enforce or otherwise settle with NISSO and DAP the parties’ agreement regarding such refund. Replidyne has provided Forest a reconciliation of all costs accrued since October 1, 2005 through December 31, 2005 under the API Supply Agreement and existing supply agreements for the manufacturing and packaging of Product. If the API Supply Agreement and Replidyne’s other existing Third Party supply agreements for manufacture and packaging of Product are not assigned to Forest, Forest’s required quantities of Drug Substance and Product will be supplied to Forest by Replidyne at Replidyne’s cost under the API Supply Agreement and other applicable Third Party agreements. Forest will bear the risk and have the benefit of currency fluctuations applied to Drug Substance and Product purchases in foreign currencies. Following the Effective Date, Replidyne shall not incur FTE costs for the account of Forest with respect to Replidyne personnel participating in activities related to the manufacture, packaging and distribution of Drug Substance, without prior mutual agreement of the parties to a plan for such activities.
Sample 1
Supply Costs. The Supply Costs of Manufacturing and supplying API of Licensed Compound for Clinical Supply shall be treated as Development Costs and shared by the Parties in accordance with Section 4.5. The Supply Costs of Manufacturing and supplying API of Licensed Compounds for Commercial Supply shall be taken into account in determining Pre-Tax Profit or Loss as, and to the extent, provided in the Financial Exhibit.
Sample 1
Supply Costs. Subject to Section 6.3, all costs incurred after October 1, 2005 related to manufacture, packaging and distribution of Drug Substance and Product will be borne by Forest; provided, however, that, [ *** ]. Replidyne has provided Forest a reconciliation of all costs accrued since October 1, 2005 through December 31, 2005 under the API Supply Agreement and existing supply agreements for the manufacturing and packaging of Product. If the API Supply Agreement and Replidyne’s other existing Third Party supply agreements for manufacture and packaging of Product are not assigned to Forest, Forest’s required quantities of Drug Substance and Product will be supplied to Forest by Replidyne at Replidyne’s cost under the API Supply Agreement and other applicable Third Party agreements. Forest will bear the risk and have the benefit of currency fluctuations applied to Drug Substance and Product purchases in foreign currencies. Following the Effective Date, Replidyne shall not incur FTE costs for the account of Forest with respect to Replidyne personnel participating in activities related to the manufacture, packaging and distribution of Drug Substance, without prior mutual agreement of the parties to a plan for such activities.
Sample 1
AutoNDA by SimpleDocs

Related to Supply Costs

  • Manufacturing Costs In the event of termination by Merck pursuant to Section 6.2, 6.3 or 6.6 above, Merck shall be entitled to [*****] (as defined herein) incurred by Merck for its Compound Delivered for the Study. [*****]

  • Development Expenses Bionics will reimburse the Company for all reasonable expenses directly associated with the development of the Lead for Bionics (including, without limitation, costs associated with animal studies and human trials), when the Company submits a request to Bionics for approval prior to incurring such expenses and such expenses are incurred with Bionics’ written approval, provided receipts for such expenses are submitted to Bionics within 30 days after such expenses are incurred. Upon receiving a request for expense authorization from the Company, Bionics will indicate to the Company whether the requested expense is authorized within 15 days for expenses up to $1,000 and within 30 days for expenses over $1,000. Bionics will reimburse the Company within 30 days of receiving reasonably detailed invoices describing the Company’s authorized expenses under this Agreement. The Company will provide those invoices to Bionics within 15 days after the end of each month in which the Company incurs any authorized expense.

  • Development Costs With respect to activities prior to the Amendment Effective Date, each Party was to pay [*] of the total Direct Development Costs of a Product incurred in accordance with the Development Budget (as defined in the Original Agreement). Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, with respect to activities on and after the Amendment Effective Date, subject to Sections 3.1.2, Alimera will be solely responsible for, and shall pay one hundred percent (100%) of, all development costs of a Product, including Direct Development Costs. Notwithstanding anything in this Article 6 of this Agreement or in any other provision of this Agreement to the contrary, (i) all payments owing by CDS hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by CDS (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), further including any penalties and interest which might have accrued with respect thereto, and further including all CDS payments deferred pursuant to that February 11, 2008 letter agreement sent by CDS and executed by CDS and Alimera regarding deferral of payments under the Original Agreement as of such date; (ii) all payments owing by Alimera hereunder with respect to development activities prior to the Amendment Effective Date are hereby deemed fully paid by Alimera (or waived, to the extent such waiver may be required), including any Development Payments, Compounded Development Payments, Determined Disputed Costs and Compounded Disputed Costs (as all defined in the Original Agreement), and further including any penalties and interest which might have accrued with respect thereto; and (iii) subject to Sections 3.1.1 and 3.1.2, from and after the Amendment Effective Date, CDS will have no liability whatsoever hereunder for any past, present or future development costs, including Direct Development Costs (which includes those incurred before, on and after the Amendment Effective Date), and instead Alimera shall have sole liability therefor.

  • Taxes and Regulatory Costs Borrower shall pay to Bank immediately upon demand, in addition to any other amounts due or to become due hereunder, any and all (i) withholdings, interest equalization taxes, stamp taxes or other taxes (except income and franchise taxes) imposed by any domestic or foreign governmental authority and related in any manner to LIBOR, and (ii) future, supplemental, emergency or other changes in the LIBOR Reserve Percentage, assessment rates imposed by the Federal Deposit Insurance Corporation, or similar requirements or costs imposed by any domestic or foreign governmental authority or resulting from compliance by Bank with any request or directive (whether or not having the force of law) from any central bank or other governmental authority and related in any manner to LIBOR to the extent they are not included in the calculation of LIBOR. In determining which of the foregoing are attributable to any LIBOR option available to Borrower hereunder, any reasonable allocation made by Bank among its operations shall be conclusive and binding upon Borrower.

  • Direct Costs Insert the major cost elements. For each element, consider the application of the paragraph entitled “Costs Requiring Prior Approval” on page 1 of these instructions.

  • Transportation Costs The cost of transporting a Warranted Part claimed to be defective to the facilities designated by the Seller and for the return therefrom of a repaired or replaced Warranted Part shall be borne by the Buyer.

  • Marketing Expenses Certain marketing expenses, such as Selected Dealer conferences, may be advanced to Selected Dealer and later deducted from the portion of the Dealer Manager Fee re-allowed to that Selected Dealer. If the offering of Shares in a Feeder Fund is not consummated, Selected Dealer will repay any such advance to the extent not previously expended on marketing expenses. Any such advance shall be deducted from the maximum amount of the Dealer Manager Fee that may otherwise be re-allowable to Selected Dealer. Notwithstanding anything herein to the contrary, as to any Feeder Fund, Selected Dealer will not be entitled to receive any Dealer Manager Fee and/or Distribution and Shareholder Servicing Fee which would cause the aggregate amount of selling commissions, dealer manager fees, Distribution and Shareholder Servicing Fees and other forms of underwriting compensation (as defined in accordance with applicable FINRA rules) received by the Dealer Manager and all Selected Dealers to exceed 10.0% of the gross proceeds raised from the sale of Shares in the Feeder Fund’s primary offering.

  • Patent Expenses Unless agreed otherwise, the Party filing a Patent Application will pay all preparation and filing expenses, prosecution fees, issuance fees, post issuance fees, patent maintenance fees, annuities, interference expenses, and attorneys’ fees for that Patent Application and any resulting Patent(s). If a license to any CRADA Subject Invention is granted to Collaborator, then Collaborator will be responsible for all expenses and fees, past and future, in connection with the preparation, filing, prosecution, and maintenance of any Patent Applications and Patents claiming exclusively licensed CRADA Subject Inventions and will be responsible for a pro-rated share, divided equally among all licensees, of those expenses and fees for non-exclusively licensed CRADA Subject Inventions. Collaborator may waive its exclusive option rights at any time, and incur no subsequent financial obligation for those Patent Application(s) or Patent(s).

  • Operating Costs Tenant shall pay to Landlord the Tenant’s Percentage of Operating Costs (as hereinafter defined) incurred by Landlord in any calendar year. Tenant shall remit to Landlord, on the first day of each calendar month, estimated payments on account of Operating Costs, such monthly amounts to be sufficient to provide Landlord, by the end of the calendar year, a sum equal to the Operating Costs, as reasonably estimated by Landlord from time to time. The initial monthly estimated payments shall be in an amount equal to 1/12th of the Initial Estimate of Tenant’s Percentage of Operating Costs for the Calendar Year. If, at the expiration of the year in respect of which monthly installments of Operating Costs shall have been made as aforesaid, the total of such monthly remittances is greater than the actual Operating Costs for such year, Landlord shall promptly pay to Tenant, or credit against the next accruing payments to be made by Tenant pursuant to this subsection 4.2.3, the difference; if the total of such remittances is less than the Operating Costs for such year, Tenant shall pay the difference to Landlord within twenty (20) days from the date Landlord shall furnish to Tenant an itemized statement of the Operating Costs, prepared, allocated and computed in accordance with generally accepted accounting principles. Any reimbursement for Operating Costs due and payable by Tenant with respect to periods of less than twelve (12) months shall be equitably prorated.

  • Royalties 8.1 In consideration of the license herein granted, LICENSEE shall pay royalties to LICENSOR as follows:

Time is Money Join Law Insider Premium to draft better contracts faster.